FDG-PET Imaging of Doxorubicin-Induced Cardiotoxicity: a New Window on an Old Problem

Matteo Bauckneht, Vanessa Cossu, Alberto Miceli, Maria Isabella Donegani, Selene Capitanio, Silvia Morbelli, Cecilia Marini, Gianmario Sambuceti

Research output: Contribution to journalReview article

Abstract

Purpose of Review: The present review focus on the published literature about the use of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in the early recognition of anthracyclines-related cardiotoxicity. Recent Findings: The application of PET/CT may represent an early predictor of subsequent cardiotoxicity in cancer patients treated with doxorubicin (DXR). However, the application of PET/CT may also extend beyond mere cardiotoxicity identification and monitoring to provide mechanistic delineation of the cardiotoxic pathophysiology. Indeed, this tool further enriched the current knowledge on energy metabolism impairment in the DXR-induced cardiotoxic cascade. Summary: The capability of FDG to selectively track the early endoplasmic reticulum pentose phosphate pathway (PPP) response to oxidative stress rather than the later occurring contractile dysfunction might imply the abrupt occurrence of metabolic abnormality during the course of chemotherapy, possibly identifying the ongoing myocardial damage in time to change the chemotherapy scheme or to initiate targeted cardioprotective treatments. Future prospective studies encompassing a specific dietary or pharmacologic preparation before FDG injection, as already performed in infectious and inflammatory heart diseases, are needed to move the obtained preclinical findings supporting the role of FDG imaging in DXR cardiotoxicity from bench to bedside.

Original languageEnglish
Article number41
JournalCurrent Cardiovascular Imaging Reports
Volume12
Issue number11
DOIs
Publication statusPublished - Nov 1 2019

Fingerprint

Doxorubicin
Drug Therapy
Pentose Phosphate Pathway
Anthracyclines
Fluorodeoxyglucose F18
Endoplasmic Reticulum
Energy Metabolism
Heart Diseases
Oxidative Stress
Prospective Studies
Injections
Cardiotoxicity
Neoplasms
Therapeutics

Keywords

  • Cardiotoxicity
  • Doxorubicin
  • Fluorodeoxyglucose
  • Oxidative stress
  • Positron emission tomography

ASJC Scopus subject areas

  • Histology
  • Applied Microbiology and Biotechnology
  • Cell Biology

Cite this

FDG-PET Imaging of Doxorubicin-Induced Cardiotoxicity : a New Window on an Old Problem. / Bauckneht, Matteo; Cossu, Vanessa; Miceli, Alberto; Donegani, Maria Isabella; Capitanio, Selene; Morbelli, Silvia; Marini, Cecilia; Sambuceti, Gianmario.

In: Current Cardiovascular Imaging Reports, Vol. 12, No. 11, 41, 01.11.2019.

Research output: Contribution to journalReview article

@article{da96fb31d3054f9f9f5f10eb1a863c11,
title = "FDG-PET Imaging of Doxorubicin-Induced Cardiotoxicity: a New Window on an Old Problem",
abstract = "Purpose of Review: The present review focus on the published literature about the use of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in the early recognition of anthracyclines-related cardiotoxicity. Recent Findings: The application of PET/CT may represent an early predictor of subsequent cardiotoxicity in cancer patients treated with doxorubicin (DXR). However, the application of PET/CT may also extend beyond mere cardiotoxicity identification and monitoring to provide mechanistic delineation of the cardiotoxic pathophysiology. Indeed, this tool further enriched the current knowledge on energy metabolism impairment in the DXR-induced cardiotoxic cascade. Summary: The capability of FDG to selectively track the early endoplasmic reticulum pentose phosphate pathway (PPP) response to oxidative stress rather than the later occurring contractile dysfunction might imply the abrupt occurrence of metabolic abnormality during the course of chemotherapy, possibly identifying the ongoing myocardial damage in time to change the chemotherapy scheme or to initiate targeted cardioprotective treatments. Future prospective studies encompassing a specific dietary or pharmacologic preparation before FDG injection, as already performed in infectious and inflammatory heart diseases, are needed to move the obtained preclinical findings supporting the role of FDG imaging in DXR cardiotoxicity from bench to bedside.",
keywords = "Cardiotoxicity, Doxorubicin, Fluorodeoxyglucose, Oxidative stress, Positron emission tomography",
author = "Matteo Bauckneht and Vanessa Cossu and Alberto Miceli and Donegani, {Maria Isabella} and Selene Capitanio and Silvia Morbelli and Cecilia Marini and Gianmario Sambuceti",
year = "2019",
month = "11",
day = "1",
doi = "10.1007/s12410-019-9517-1",
language = "English",
volume = "12",
journal = "Current Cardiovascular Imaging Reports",
issn = "1941-9066",
publisher = "Current Medicine Group",
number = "11",

}

TY - JOUR

T1 - FDG-PET Imaging of Doxorubicin-Induced Cardiotoxicity

T2 - a New Window on an Old Problem

AU - Bauckneht, Matteo

AU - Cossu, Vanessa

AU - Miceli, Alberto

AU - Donegani, Maria Isabella

AU - Capitanio, Selene

AU - Morbelli, Silvia

AU - Marini, Cecilia

AU - Sambuceti, Gianmario

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Purpose of Review: The present review focus on the published literature about the use of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in the early recognition of anthracyclines-related cardiotoxicity. Recent Findings: The application of PET/CT may represent an early predictor of subsequent cardiotoxicity in cancer patients treated with doxorubicin (DXR). However, the application of PET/CT may also extend beyond mere cardiotoxicity identification and monitoring to provide mechanistic delineation of the cardiotoxic pathophysiology. Indeed, this tool further enriched the current knowledge on energy metabolism impairment in the DXR-induced cardiotoxic cascade. Summary: The capability of FDG to selectively track the early endoplasmic reticulum pentose phosphate pathway (PPP) response to oxidative stress rather than the later occurring contractile dysfunction might imply the abrupt occurrence of metabolic abnormality during the course of chemotherapy, possibly identifying the ongoing myocardial damage in time to change the chemotherapy scheme or to initiate targeted cardioprotective treatments. Future prospective studies encompassing a specific dietary or pharmacologic preparation before FDG injection, as already performed in infectious and inflammatory heart diseases, are needed to move the obtained preclinical findings supporting the role of FDG imaging in DXR cardiotoxicity from bench to bedside.

AB - Purpose of Review: The present review focus on the published literature about the use of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in the early recognition of anthracyclines-related cardiotoxicity. Recent Findings: The application of PET/CT may represent an early predictor of subsequent cardiotoxicity in cancer patients treated with doxorubicin (DXR). However, the application of PET/CT may also extend beyond mere cardiotoxicity identification and monitoring to provide mechanistic delineation of the cardiotoxic pathophysiology. Indeed, this tool further enriched the current knowledge on energy metabolism impairment in the DXR-induced cardiotoxic cascade. Summary: The capability of FDG to selectively track the early endoplasmic reticulum pentose phosphate pathway (PPP) response to oxidative stress rather than the later occurring contractile dysfunction might imply the abrupt occurrence of metabolic abnormality during the course of chemotherapy, possibly identifying the ongoing myocardial damage in time to change the chemotherapy scheme or to initiate targeted cardioprotective treatments. Future prospective studies encompassing a specific dietary or pharmacologic preparation before FDG injection, as already performed in infectious and inflammatory heart diseases, are needed to move the obtained preclinical findings supporting the role of FDG imaging in DXR cardiotoxicity from bench to bedside.

KW - Cardiotoxicity

KW - Doxorubicin

KW - Fluorodeoxyglucose

KW - Oxidative stress

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=85075205191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075205191&partnerID=8YFLogxK

U2 - 10.1007/s12410-019-9517-1

DO - 10.1007/s12410-019-9517-1

M3 - Review article

AN - SCOPUS:85075205191

VL - 12

JO - Current Cardiovascular Imaging Reports

JF - Current Cardiovascular Imaging Reports

SN - 1941-9066

IS - 11

M1 - 41

ER -